There is renewed interest in psychedelics, such as psilocybin, as therapies for multiple difficult-to-treat psychiatric disorders. Even though psychedelics can induce highly pleasant or aversive experiences, depending on multiple personal and environmental factors, there is little research into how such experiences impact post-acute mood-altering actions. Here we aimed at offsetting this gap....
Abstract Adolescent depression is a significant public health concern, yet treatment options remain limited, particularly due to age- and sex-related differences in antidepressant efficacy. This study explored the rapid and long-lasting antidepressant-like potential of psilocybin in adolescent Sprague-Dawley rats, examining acute and repeated oral dosing effects while incorporating sex as a...
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use...
W ostatnich latach rosnące zainteresowanie uważnością (ang. mindfulness) znajduje odzwierciedlenie nie tylko w naukach społecznych, ale także w logopedii. Badania pokazują, że regularne stosowanie metod opartych na uważności (ang. Mindfulness‑Based Interventions – MBI) przynosi korzyści osobom z depresją, chorobami nowotworowymi, przewlekłymi bólami czy uogólnionymi zaburzeniami lękowymi....
Dr. Alaina M. Jaster is a postdoctoral scholar in the Department of Psychiatry and Behavioral Neurosciences at Wayne State University. She currently serves on the trainee editorial board of Psychedelic Medicine, the journal for the International Society for Research on Psychedelics (ISRP), and is part of the Society's Diversity Equity Inclusion and Accessibility committee. Jaster is also part...
In this review, studies focusing on the therapeutic use of psychedelics for treating mental health disorders published since 2010 have been examined. A systematic literature search was conducted using Medline and EBSCO. After extracting data from 19 papers, an analysis was performed. Critical evidence highlighting the effectiveness of psychedelic drugs in treating depression, anxiety,...
Abstract Psilocybin is a psychedelic tryptamine that has emerged as a potential candidate for the treatment of a variety of conditions, including treatment resistant depression and post-traumatic stress disorder. Clinical trials which have assessed the efficacy of psilocybin for these conditions report a rapid and sustained improvement in patient- and clinician-rated depression scores. The...
Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and a superior safety profile. This scoping review aims to assess and synthesise existing literature on the clinical use of arketamine in humans. This review...
Recent studies indicate that nitrous oxide (N2O), a gaseous anesthetic and an NMDA (N-methyl-D-aspartate) receptor antagonist, produces rapid antidepressant effect in patients suffering from treatment-resistant depression. Our recent work implies that hypothermia and reduced energy expenditure are connected with antidepressant-induced activation of TrkB neurotrophin receptors - a key regulator...
Research has shown that 20% of Czech teachers suffer with burnout symptoms and 65% are at risk of burning out, which suggests that it is essential to continue addressing the issue of stress in Czech teachers. The main objective of this study was to evaluate a self-compassion and mindfulness-based professional development program for primary school teachers in the Czech Republic. Five schools...